• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
InterMune, Inc. (ITMN) - Financial and Strategic SWOT Analysis Review - Product Image

InterMune, Inc. (ITMN) - Financial and Strategic SWOT Analysis Review

  • Published: April 2013
  • Region: Global
  • 45 pages
  • GlobalData

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pharmasset, Inc
  • Tibotec BVBA
  • MORE

Summary

InterMune, Inc. (InterMune) is a biotechnology company. It focuses on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. The company's product portfolio comprises of pirfenidone, an orally active, small molecule compound, indicated for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is marketed in Germany, Austria, Belgium, Denmark, France, Iceland, Luxembourg, Norway and Sweden. It is also commercialized in Canada. The product is in a Phase III clinical trial for obtaining regulatory registration in the US.

InterMune, Inc. Key Recent Developments

Feb 21, 2013: InterMune Reports Revenue Of $8.2m In Q4 2012
Feb 14, 2013: InterMune Appoints Sean Nolan As Chief Business Officer
Nov 07, 2012: InterMune Reports Revenue Of $7.5m In Q3 2012
Jul 23, 2012: InterMune Reports Revenue Of $5.5m In Q2 2012
Apr 26, 2012: InterMune Reports Revenue Of $8.9m In Q1 2012

This comprehensive SWOT profile of InterMune, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
InterMune, Inc. - Key Facts
InterMune, Inc. - Key Employees
InterMune, Inc. - Key Employee Biographies
InterMune, Inc. - Major Products and Services
InterMune, Inc. - Pharmaceutical Pipeline Products Data
InterMune, Inc., Pipeline Products by Therapy Area
InterMune, Inc., Pipeline Products by Development Phase
InterMune, Inc. - History
InterMune, Inc. - Company Statement
InterMune, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
InterMune, Inc. - Business Description
InterMune, Inc. - SWOT Analysis
SWOT Analysis - Overview
InterMune, Inc. - Strengths
Strength - Research and Development Activities
Strength - Lead Product Candidate: Pirfenidone
Strength - Patent Portfolio
InterMune, Inc. - Weaknesses
Weakness - Lawsuits and Legal Proceedings
Weakness - History of Losses
InterMune, Inc. - Opportunities
Opportunity - Commercial Plan
Opportunity - Changing Demographics
Opportunity - Biotech Focus
InterMune, Inc. - Threats
Threat - Delay in the Planned Clinical Trials
Threat - Uncertain R&D Outcome
Threat - Tightening of the FDA’s Regulatory Oversight
InterMune, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
InterMune, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
InterMune, Inc., Recent Developments
Feb 21, 2013: InterMune Reports Revenue Of $8.2m In Q4 2012
Feb 14, 2013: InterMune Appoints Sean Nolan As Chief Business Officer
Nov 07, 2012: InterMune Reports Revenue Of $7.5m In Q3 2012
Jul 23, 2012: InterMune Reports Revenue Of $5.5m In Q2 2012
Apr 26, 2012: InterMune Reports Revenue Of $8.9m In Q1 2012
Feb 09, 2012: InterMune Names Jonathan Leff As Executive Vice President Of R&D
Feb 09, 2012: InterMune Reports Revenue Of $7.8m In Q4 2011
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
InterMune, Inc., Key Facts
InterMune, Inc., Key Employees
InterMune, Inc., Key Employee Biographies
InterMune, Inc., Major Products and Services
InterMune, Inc., Number of Pipeline Products by Therapy Area
InterMune, Inc., Number of Pipeline Products by Development Stage
InterMune, Inc., Pipeline Products By Therapy Area and Development Phase
InterMune, Inc., History
InterMune, Inc., Subsidiaries
InterMune, Inc., Key Competitors
InterMune, Inc., Ratios based on current share price
InterMune, Inc., Annual Ratios
InterMune, Inc., Interim Ratios
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
InterMune, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
InterMune, Inc., Pipeline Products by Therapy Area
InterMune, Inc., Pipeline Products by Development Phase
InterMune, Inc., Performance Chart (2008 - 2012)
InterMune, Inc., Ratio Charts
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
InterMune, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Pharmasset, Inc
Merck & Co., Inc.
GlaxoSmithKline plc
Gilead Sciences, Inc.
Tibotec BVBA

Note: Product cover images may vary from those shown

RELATED PRODUCTS